xanax xr 3 mg
Each XANAX XR extended-release tablet, for oral administration, contains 0.5 mg, 1 mg, 2 mg, or 3 mg of alprazolam. The inactive ingredients are lactose, magnesium stearate, colloidal silicon dioxide, and hypromellose. In addition, the 1 mg and 3 mg tablets contain D & Cyellow No. 10 and the 2 mg and 3 mg tablets contain FD&C blue No. 2.
imprint xanax xr 3 mg
Pill with imprint X 3 is Green, Three-sided and has been identified as Xanax XR 3 mg. It is supplied by Pfizer U.S. Pharmaceuticals Group. Xanax XR is used in the treatment of panic disorder and belongs to the drug class benzodiazepines. There is positive evidence of human fetal risk during pregnancy. Xanax XR 3 mg is classified as a Schedule 4 controlled substance under the Controlled Substance Act (CSA).
xanax xr 3 mg is in a group of drugs called benzodiazepines (ben-zoe-dye-AZE-eh-peens). Alprazolam affects chemicals in the brain that may become unbalanced and cause anxiety.
xanax xr 3 mg is used to treat anxiety disorders, panic disorders, and anxiety caused by depression.
XANAX XR (extended-release) Tablets are available as follows:
- 0.5 mg (white, pentagonal-shaped tablets debossed with an “X” on one side and “0.5” on the other side) Bottles of 60 NDC 0009-0057-07
- 1 mg (yellow, square-shaped tablets debossed with an “X” on one side and “1” on the other side) Bottles of 60 NDC 0009-0059-07
- 2 mg (blue, round-shaped tablets debossed with an “X” on one side and “2” on the other side) Bottles of 60 NDC 0009-0066-07
- 3 mg (green, triangular-shaped tablets debossed with an “X” on one side and “3” on the other side) Bottles of 60 NDC 0009-0068-0
Store at 25o C (77o F); excursions permitted to 15–30o C (59–86oF)
Switch from XANAX (immediate-release) Tablets to XANAX XR (extendedrelease) Tablets
Patients who are currently being treated with divided doses of XANAX (immediate-release) Tablets, for example 3 to 4 times a day, may be switched to XANAX XR Tablets at the same total daily dose taken once daily. If the therapeutic response after switching is inadequate, the dosage may be titrated as outlined above.
DOSAGE AND ADMINISTRATION
XANAX XR Tablets may be administered once daily, preferably in the morning. The tablets should be taken intact; they should not be chewed, crushed, or broken. The suggested total daily dose ranges between 3 to 6 mg/day.
Dosage should be individualized for maximum beneficial effect. While the suggested total daily dosages given will meet the needs of most patients, there will be some patients who require doses greater than 6 mg/day. In such cases, dosage should be increased cautiously to avoid adverse effects.
Dosing in Special Populations
In elderly patients, in patients with advanced liver disease, or in patients with debilitating disease, the usual starting dose of XANAX XR is 0.5 mg once daily. This may be gradually increased if needed and tolerated (see Dose Titration). The elderly may be especially sensitive to the effects of benzodiazepines.
Treatment with XANAX XR may be initiated with a dose of 0.5 mg to 1 mg once daily. Depending on the response, the dose may be increased at intervals of 3 to 4 days in increments of no more than 1 mg/day. Slower titration to the dose levels may be advisable to allow full expression of the pharmacodynamic effect of XANAX XR.
Generally, therapy should be initiated at a low dose to minimize the risk of adverse responses in patients especially sensitive to the drug. Dose should be advanced until an acceptable therapeutic response (ie, a substantial reduction in or total elimination of panic attacks) is achieved, intolerance occurs, or the maximum recommended dose is attained.
In controlled trials conducted to establish the efficacy of XANAX XR Tablets in panic disorder, doses in the range of 1 to 10 mg/day were used. Most patients showed efficacy in the dose range of 3 to 6 mg/day. Occasional patients required as much as 10 mg/day to achieve a successful response.
XANAX XR Tablets are contraindicated in patients with known sensitivity to this drug or other benzodiazepines. XANAX XR is contraindicated with ketoconazole and itraconazole, since these medications significantly impair the oxidative metabolism mediated by cytochrome P450 3A (CYP3A).